Attached files

file filename
EX-21.1 - EXHIBIT 21.1 SUBSIDIARIES OF PROGENICS PHARMACEUTICALS, INC. - PROGENICS PHARMACEUTICALS INCex21_112312014.htm
EX-23.1 - EXHIBIT 23.1 CONSENT OF ERNST & YOUNG LLP - PROGENICS PHARMACEUTICALS INCex23_112312014.htm
EX-32.1 - EXHIBIT 32.1 CERTIFICATION - PROGENICS PHARMACEUTICALS INCex32_112312014.htm
EX-31.1 - EXHIBIT 31.1 CERTIFICATION - PROGENICS PHARMACEUTICALS INCex31_112312014.htm
EX-31.2 - EXHIBIT 31.2 CERTIFICATION - PROGENICS PHARMACEUTICALS INCex31_212312014.htm
EXCEL - IDEA: XBRL DOCUMENT - PROGENICS PHARMACEUTICALS INCFinancial_Report.xls
10-K - PROGENICS PHARMACEUTICALS INCform10_k12312014.htm
EX-32.2 - EXHIBIT 32.2 CERTIFICATION - PROGENICS PHARMACEUTICALS INCex32_212312014.htm
Exhibit 12.1
 
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
 
 
 
Years Ended December 31,
 
 
 
2014
   
2013
   
2012
   
2011
   
2010
 
Determination of earnings (loss):
 
   
   
   
   
 
Income (loss) from operations
 
$
4,410
 
 
$
(42,934
)
 
$
(35,431
 
$
10,381
 
 
$
(69.820
)
Add:
                                       
Fixed charges
   
373
     
710
     
410
     
695
     
709
 
 
                                       
Earnings (loss), as adjusted
 
$
4,783
 
 
$
(42,224
)
 
$
(35,021
 
$
11,076
 
 
$
(69,111
)
 
                                       
Fixed charges:
                                       
 
                                       
Estimate of interest within rental expense
   
373
     
710
     
410
     
695
     
709
 
 
                                       
Fixed charges
 
$
373
   
$
710
   
$
410
   
$
695
   
$
709
 
 
                                       
Preferred stock dividends
 
$
-
   
$
-
   
$
-
   
$
-
   
$
-
 
 
                                       
Ratio of earnings (loss) to fixed charges and preferred stock dividends
   
13
     
*
     
*
     
16
     
*
 
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)
 
$
-
   
$
42,934
   
$
35,431
   
$
-
   
$
69,820
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1)
For the years ended 2010, 2012 and 2013, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.